Company intelligence / Profile preview

Augmenix

Bedford, Massachusetts, USA

Ownership: Private
Development stage: Other

Overview

Augmenix is a medical technology company focused on improving outcomes in radiation oncology through the development of hydrogel-based spacers. The company's flagship product, SpaceOAR Hydrogel, is an absorbable material injected between the prostate and rectum to reduce radiation exposure to healthy tissue during prostate cancer treatment. This technology significantly minimizes rectal toxicity and long-term side effects for patients undergoing radiotherapy. Founded in 2008 as a spin-out from Incept LLC, Augmenix was acquired by Boston Scientific in 2018 to expand its urology and pelvic health portfolio.

Therapeutic areas: OncologyOther
Modalities: Hydrogel-based drug delivery therapyDevice
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Augmenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Augmenix.

Explore the full profile